The FDA has raised questions about the efficacy of NeurogesX's prescription-strength capsaicin patch Qutenza in relieving pain related to nerve damage commonly associated with HIV, according to a Bloomberg Businessweek report.
The news sent the company's stock to its lowest level since March 2009. NeurogesX hasn't reported a profit since the company began selling shares in 2007, and the stock has fallen 83 percent in the past year.
Advisors are scheduled to meet with regulators tomorrow, and a final decision is expected by March 7.
Related Articles on Pain Management:
Study: Spinal Cord Stimulation Effective for HIV Neuropathy
Pain Center of Arizona Opens New Clinic in Phoenix
Pain Physicians: What is the Biggest Factor Contributing to Your Practice's Profitability?
The news sent the company's stock to its lowest level since March 2009. NeurogesX hasn't reported a profit since the company began selling shares in 2007, and the stock has fallen 83 percent in the past year.
Advisors are scheduled to meet with regulators tomorrow, and a final decision is expected by March 7.
Related Articles on Pain Management:
Study: Spinal Cord Stimulation Effective for HIV Neuropathy
Pain Center of Arizona Opens New Clinic in Phoenix
Pain Physicians: What is the Biggest Factor Contributing to Your Practice's Profitability?